The EAHP
Wednesday 27 March 2019
Daily dose
Information that makes you feel good!
AZ_EAHP_PRINT.pdf
1
14.01.19
11:16
24th Congress March 2019 Barcelona
“Personalised Hospital Pharmacy – meeting the needs of every patient” CONGRESS AGENDA
KEYNOTE 1 PREVIEW
Full programme of activities
The OMICs approach – the buzz that makes the world go round!
Page 2
Page 3
EAHP SURVEY Survey activities & results
Page 8
Welcome to the EAHP Daily Dose! Available hot off the press on Wednesday and Thursday of the Congress, this newspaper will come in handy to plan your day or brush up on some important issues. From a mixture of preview articles of sessions and seminars, to interviews with some of the key people behind the Congress and ‘at a glance’ overviews of the day’s schedule: the EAHP Daily Dose is a must–read for all attendees!
Welcome to our 24th Congress!
PharmDr. Petr Horák, EAHP President
Dear Colleagues, Let me welcome you to Barcelona, a city which has more than 2000 years of history and yet it is one of the most modern cities in the Old Continent. EAHP is very pleased to invite you to the
24th EAHP Congress, which takes place in this gorgeous city from 27-29 March 2019. The Congress theme is “Personalised Hospital Pharmacy – meeting the needs of every patient”. The title itself says a lot. The origins of the pharmacy were very much personalised and recently we have been rediscovering the need for tailored medication and approach to treatment for different patient groups and individuals. The scientific program of the Congress is also tailored to the needs of individual hospital pharmacists and their interest groups as the Congress offers the possibility to choose between many parallel sessions, keynote presentations, workshops and symposia. EAHP believes that the role of hospital pharmacists in personalised medication is the key to success. Therefore, we have prepared an advanced program that will serve as the source of knowledge and inspiration that are needed for our future role and engagement in personalised medication.
The EAHP Congress is also an opportunity to meet colleagues from Europe and all over the world, to share experience and ideas and to learn from each other. EAHP is fostering advancement in hospital pharmacy practice for the benefit of our patients. Sharing expertise and best practices is certainly one of the best ways to accelerate our success. The EAHP Congress, one of the the largest hospital pharmacy Congresses in Europe, provides an optimal platform for this sharing and education but also for the pure joy of meeting fellow hospital pharmacists, colleagues and friends. It is my great honour to invite you, on behalf of EAHP, to our Congress. PharmDr. Petr Horák, EAHP President
Tevadaptor® continues to demonstrate safety with 2 new peer-reviewed articles TDPT-IL-00129
www.tevadaptor.com
Visit us at booth
#25 Also visit our new website!
24th Congress of the EAHP
2
WEDNESDAY, 27 MARCH 2018 DATE/TIME
MEETINGS/EVENTS
ROOM
07.00
Registration opens (individuals, groups and exhibitors)
Entrance hall
08.30 – 10.15
Opening ceremony & Keynote 1 – The OMICS approach - the buzz that makes the world go round! Forum Auditorium G. Ecker*
10.15
Exhibition opens
Area 1+2+3
10.15 – 11.45
Coffee break
Area 1+2+3
10.30 – 12.00
Award nominee oral presentations
116
10.30 – 11.45
Good Practice Initiative oral presentations
115
10.45 – 11.15
Bayer – Meet the Expert
Bayer - Stand 19 Exhibition area
Synergy Satellite Event - Biosimilars - available yet sometimes missing - the challenge of procurement (sponsored by an educational grant from Amgen)
12.00 – 13.30
Forum Auditorium
I. Huys; J. Kent; A. Alcobia
13.30 – 14.45
Lunch
Area 1+2+3
13.45 – 14.15
Bayer – Meet the Expert
Bayer - Stand 19 Exhibition area
14.30 – 18.30
Student Programme: How can hospital pharmacists implement antimicrobial stewardship to ensure rational use of antimicrobials? A. Tonna; T. Hoppe-Tichy
124
Synergy Interactive Session - Anticoagulation – improving efficacy and preventing side effects (sponsored by an educational grant from Bayer) L. Van der Linden*; C. Quintens
14.45- 16.15 14.45- 16.15
14.45 - 16.15
16.15 – 17.00
Seminars Seminar IG1 - Implementation science - the inside story M. Teichert*; L. Poulsen
113
Seminar SPD2 - Managed entry agreements - risk sharing and beyond S. Brown; C. Ferri
115
Seminar SPD1 - Health technology assessment - one step further! J. Perelman; M.J. Lamas
117
Seminar PC1 - Individual preparations - time to change the law? H. Scheepers; P. Le Brun
211
Interactive Session 1 - The role of pharmacogenomics in medication optimisation R. Turner; B. Sproule
125
Industry Sponsored Satellites MSD “Shifting Paradigms For Critically Ill Patients With Gram-Negative Infections: Redefining Treatment Strategies”
111
Accord Healthcare “Biosimilars - Improving Access and Optimising Practice”
114
Coffee break
Area 1+2+3 Synergy Satellite Event – Biosimilars - challenging misconceptions, optimising uptake, maximising value (financial support was provided by Pfizer Limited as a Medical and Educational Goods and Service) M. Flume*; A. McWhirter
17.00- 18.30
116
116
Seminars
116
Seminar CPS1 - Responding to individual metabolism by genomics and metabolomics C. Nievergelt; S. J. Krähenbühl
113
Seminar PC2 - Preparation for neonates - a sensitive population M. Paulsson*; I. Sviestina
114
Seminar PC3 - From gene therapy to cell therapy - what about hospital pharmacy? T. Hoppe-Tichy*; N. A. A. de Miranda Seminar ER2 - European Hospital Pharmacists - the future in the making (this session will run once only) R. Frontini*; S. Kohl; E. Fernandez de Gamarra; C. Plesan
115 117
24th Congress of the EAHP
3
Seminar PC4 - Radiopharmacy - does it glow in the dark? E-M. Klebermass, G. Bormans
125
Seminar PQ1 - Drug-related hospital admissions - detection and prevention O. Dalleur; S. Thevelin; E. Uitvlugt
211
Workshop 4 - Pharmacist-patient relationship in clinical trials B. Brignolo Ottolini; S. V. Rossi
124
Workshop 2 - To make or to buy? D. Devolder; T. Storme* 17.00 – 18.30
127
Industry sponsored satellites Roche “Supressing now progression in Multiple Sclerosis”
11
19.00 – 20.00
Get together reception
Area 1+2+3
19.00 - 20.00
Poster walk - Join the Scientific Committee during their evaluation of the posters selected for the Poster Walk
Area 3
KEYNOTE 1: PREVIEW
The OMICs approach – the buzz that makes the world go round! At a glance - Terminology The English ending omics generally refers to a field of study in biology. Examples are genomics (i.e. study the genomes), proteomics (i.e. study of the proteins) or metabolomics (i.e. study of the metabolites). Omics aims at the collective characterization and quantification of biological molecules that translate into the structure, function, and dynamics of an organism or organisms. The closely related suffix -ome addresses the objects of study of such fields, such as the genome, proteome or metabolome respectively.
O
mics technologies form the pillars of so called systems medicine. Systems medicine is an interdisciplinary study field looking at various systems of the human body as part of an integrated whole. It considers interactions within the human body in light of patient’s genomics, behaviour and environment.
K E Y N OT E
1
Forum Auditoriu m Wednesd ay 27 March 8.30 – 10.1 5
Omics technologies are vital throughout all phases of pharmaceutical research and development. In short, data generated are essential for understanding disease ethology, identifying druggable targets, and demonstrating clinical efficacy and safety. In other words, omics data are useful for managing the quality of a drug throughout its lifecycle. (See picture*) Based on the number of drugs approved for various types of cancers and genetic diseases, it is evident that omics technologies are and will continue to be an important part of pharmaceutical productivity. The speaker of the first keynote will take us on a dizzying journey through the various types of omics technologies and their importance and relevance for the (r)evolution of medicines and pharmaceutical drug development. Gerhard Ecker is Professor of Pharmacoinformatics at the University of Vienna and Dean of the Faculty of Life Sciences. Given his scientific and practice background, Prof. Dr. Ecker is best qualified to accomplish the task of also shedding light on challenges lying in the omics areas. Fasten your seatbelt and join us on the ride through the omics world! Gunar Stemer, EAHP Scientific Committee Member
*Jane P. F. Bai, Ioannis N. Melas, Junguk Hur & Ellen Guo (2018) Advances in omics for informed pharmaceutical research and development in the era of systems medicine, Expert Opinion on Drug Discovery, 13:1, 1-4, DOI: 10.1080/17460441.2018.1394839
EAHP warmly thanks our industry partners for their continued commitment to supporting the goals of hospital pharmacists. PLATINUM PARTNERS
GOLD PARTNER
CORPORATE PARTNERS
24th Congress of the EAHP
4
What to look out for at the congress Dear Congress participants, We are so pleased to welcome you to the 2019 Congress and we have much news to share with you. In line with the theme of the Congress, the objective this year is to support individual hospital pharmacists to actively engage in personalised medication and therapies for different patient groups and individuals. Before you submerse yourself in the scientific program, here’s a quick look at our new projects and initiatives.
Thursday, March 28th at 13:30) and provides on overview on the EU regulatory requirements for biosimilar approval, examples on how their use in clinical settings has been supported in various countries and suggestions on how to construct your own uptake increase strategy.
This year’s programme features three key-note presentations, five Synergy satellite sessions, numerous presentations and plenty of surprises! The Synergy Satellite sessions – accredited as educational events – are based on the content created by our Scientific Committee who took into account your learning needs and the latest scientific developments in the field. Three Synergy Satellites focus on biosimilars.
Following suit, the third session on “Biosimilars in haematooncology - new blood, old questions” (sponsored by an educational grant from Sandoz) was prompted by the recent availability of rituximab biosimilars and it will cover the EU approval regulatory requirements as applied to oncohaematology therapy, the biased trends of change in first line therapy and recommendations on how to implement biosimilar of monoclonal antibodies used in Non-Hodgkin Lymphoma and other hematologic diseases. It will take place on Thursday, March 28th at 15:45 (it will be repeated on Friday, March 29th at 09:00).
The first session, entitled “Biosimilars – available yet sometimes missing – the challenge of procurement” (sponsored by an educational grant from Amgen), will take place on Wednesday, March 27th at 12:00 and focuses on procurement and tendering practices related to biosimilars in order to avoid supply risks as well as give you more insight on the latest switching data from a reference to a biosimilar medicine in order to clarify the major efficacy and safety controversies that persist.
The fourth session on “Anticoagulation – improving efficacy and preventing side effects” (sponsored by an educational grant from Bayer) will be organised on Wednesday, March 27th at 14:45 (it will be repeated on Thursday, March 28th at 08:45). The topic targets the need to educate hospital pharmacists on the correct use and the risks of anticoagulant drugs, their appropriate use after a hospital stay as well as the opportunities of setting up and participating in “anticoagulation stewardship programmes”.
The second session on “Biosimilars: challenging misconceptions, optimising uptake, maximising value” (financial support was provided by Pfizer Limited as a Medical and Educational Goods and Service) will take place on Wednesday, March 27th at 17:00 (it will be repeated on
For a fresh start on Thursday, March 28th, one of the most exciting sessions this year is the Synergy Satellite “Facing Brexit and FMD - Is Europe ready for the double “storm”?”, starting at 07:00 sharp and it will address crucial EU-level developments (Brexit, the EMA’s relocation, FMD compliance
Programme highlights
and their impact on medicine accessibility) that need to be adapted to inside the hospital pharmacy so as to mitigate the negative impact that these might have on patients’ care. The three keynote presentations will provide you, firstly, with excellent information on the latest innovations in omics technologies and their massive impact on pharmaceutical research, drug target discovery and validation as well as toxicity assessment. The second keynote will address the need for hospital pharmacists to look out for Clinical Human Factors and their potential to improve clinical, managerial and organisational practice. The third will shed more light on the reasons behind the differences in affordability and accessibility of drugs in different European healthcare settings.
Jennie De Greef , EAHP Chief Operating Officer
New this year EAHP continues its efforts to go green while you save time and room in your bag
Statements and their implementation: where are we and what’s next
We at the EAHP have decided to lower our carbon footprint during the Congress in terms of reducing overall paper usage. Therefore, this year, Congress participants will be able to download, not print their attendance certificates. The same holds true for the Accreditation Council for Pharmacy Education (ACPE) certificates. Downloads of both certificates may begin directly from the new portal after the event officially ends. In order to comply with ACPE requirements, participants must answer the evaluation surveys after each session attended. Please note that all session surveys must be completed in order to be able to obtain the certificate! To make things as easy as possible, the surveys will be available on the new portal which is accessible either online directly or via the Cyber Café. Your feedback will help us immensely in improving the Congress programme.
In tracking the degree of implementation of the 44 European Statements of Hospital Pharmacy, EAHP is currently preparing a report on the latest results of the 2018 EAHP’s Statements Survey. This round focused on Sections 1, 3 and 4 and found that awareness has continued to increase over the past 4 years thanks to the dedicated team together with all the national ambassadors. Also, it showed that Statement 1.1. on working collaboratively within multidisciplinary teams in order to achieve the responsible use of medicines is, at the same time, highest on the priority list and the most challenging in terms of practical implementation. Want to learn more about EAHP’s Statement Surveys? Speak to our Implementation Team at stand #32.
QR codes for all
Try out the Self-assessment Tool for hospital pharmacists
To help you share your poster and to let your colleagues learn more about your work on the spot, EAHP has created a new tool! Unique QR codes are added to the printed posters and offer different perks, depending on your interests. If you are an author, you can now download a PDF version of your poster. If you are a participant, you can now easily see the online version of a specific poster and gain access to the virtual Poster Walk. The latter will be available via the “Online abstract poster walk” section of EAHP’s website both during and after the Congress. The QR code is applied on the bottom part of the posters so anyone, anywhere can instantly access, download and share the posters with their colleagues!
The Self-assessment Tool (SAT) is a web-portal that allows hospital pharmacists to assess the level of implementation of the 44 European Statements of Hospital Pharmacy within their own hospitals. By participating in this evaluation, hospital pharmacists will not only have a better grasp over the Statements’ implementation level within their own hospitals but will also be able to compare their implementation level to other hospitals at both the national and European level. Most importantly, upon completing the assessment, which can be updated at any time, the system will provide a tailor-made action plan and evidence-based resources for improvement. Want to see the tool in action? Drop by stand #32 and talk to the EAHP staff.
New and improved Congress app
Latest must-reads
Because we are always striving to improve our Congress services, this year we invite you to download our new and improved dedicated app. Many thanks go out to Bayer for their continued support of this service! The app was created to help you navigate through this year’s rich content via a redesigned programme agenda so that you don’t miss out on any of your flagged interests. Our matchmaking feature was also given a facelift while keeping its main features: finding other delegates with similar interests and easier networking via the business card request. You will still be able to share your comments, experiences and special moments. Stay connected and happy navigation!
Want to read up on EAHP’s latest publications? Then look in your Congress bag for the flyers on EAHP’s 2018 Medicines Shortages Survey and see, per country, what types of medicines are most frequently in shortage and the estimated impact this has on patient care. We thank Amgen for providing a grant to assist EAHP in its efforts to combat shortages. You will also find in your bags our flyer with information on the SAT and Statement Implementation Learning Collaborative Centres (SILCC). Another new publication this year, which will be available via a dedicated QR code in the Congress programme book, is EAHP’s 2018 Annual Report which presents our key activities and future
plans in advancing the hospital pharmacy profession. Want to have a quick chat about our publications? Drop by stand #32 and talk to the EAHP staff.
Look out for this year’s Synergy Masterclass EAHP is delighted to announce its second Synergy Masterclass that will take place from 4-5 October 2019 in Brussels, Belgium. Registration will be opened during the Congress. Please note that if you register during the Congress (at the Cyber Café, the EAHP website and the congress app), you will receive a 10% discount and you will have 30 days to pay after the Congress ends. This year’s theme is “Procurement, tendering and decision-making processes in the hospital setting” focusing on the crucial role of the hospital pharmacist in managing increasing medication costs via value-based procurement and tendering in the hospital setting. The two-day event will feature seminars by experts on EU procurement legislation, as well as practical guidance on how to formulate additional evaluation criteria, other than the price itself (e.g. patient safety issues, environmental aspects, quality-based factors and innovative characteristics). This event is open to all healthcare professionals. EAHP would like to thank Amgen for its continuous support for the Synergy Masterclasses via educational grants. The masterclasses are accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Let’s talk policy! The EAHP has been busy all throughout 2018 in monitoring, developing and engaging in EU-level activities and policies with the aim to represent and promote the role of hospital pharmacists. Our major policy priorities have been firstly, leveraging the role of the hospital pharmacist in combatting antimicrobial resistance, secondly, securing Union action on the pan-European health threat of medicines shortages and, thirdly, promoting and enabling the safe and rational use of medicines for patients. We are especially pleased with the huge success of the 2018 Medicines Shortages survey and the interest it sparked in European decision-making bodies. We will be sure to continue promoting its results throughout 2019. Do you want to find out more about EAHP’s policy priorities and discuss how we’ve been pursuing them? Read all about them in the Daily Dose or drop by stand #32 and talk to the staff.
24th Congress of the EAHP
5
SYNERGY EVENT: PREVIEW & SPEAKERS
SYNERGY SATELLITE EVENT The EAHP invites you to attend the 2019 Synergy Satellite Session:
12:00 to 13:30, Room Forum Auditorium
Biosimilars – the challenge of procurement
B
efore attending this Synergy event you will ask yourself what challenge do we actually face? If the top experts at the European Medicines Agency (EMA) have declared that biosimilars follow the best quality standards and have shown to be safe and effective, why can’t we just buy them as we do with other drugs, such as omeprazole or amoxicillin? Unfortunately, life is not that simple. Biosimilars are, as the name implies, biological drugs. More specifically, the main issue today are monoclonal antibodies such as infliximab, trastuzumab or rituximab. These are huge molecules with complex manufacturing processes. For these drugs, the demonstration of similarity requires real clinical trials, typically involving hundreds of patients in at least one of the disease settings where the drug is supposed to be used. So the EMA will say that the biological drug “whatevermaB” from company A and “whatevermaB” from company B are similar to the reference product “innovator whatevermaB”. However, they do not tell us that “whatevermaB” of
company A is a biosimilar of “whatevermaB” produced by company B. And then the questions arise: can we switch from A to B as we do from reference to A or B? Can we switch at all times or must we wait some time because of eventual immune response? Have all the biosimilars of a given reference “maB” been subject to clinical trials in the same disease setting? With the same results ? Are they really similar to one another? There are quite some clinical and regulatory issues to be discussed in this Synergy seminar, maybe just for this there are good reasons for you to attend. But life is not just concepts and ideas. Real operational issues are there to be solved. For instance, if we come to the conclusion that we cannot switch at ease between biosimilars, how do we manage the existence of several drugs in the hospital pharmacy for the same active substance? And how to we design tenders that are effective in economical terms but preserve the needs of patients?
Medicine Shortages – only EU-level action can help lower their impact
F
Hospital pharmacists have been working on raising awareness among prescribers about the difficulties that medicines shortages cause for their daily work. In addition, they have proactively tried to share information with other healthcare professionals in their working environment on how medicines shortages are managed and continuity of supply is ensured. All this at the same time as investing individual shortages and sourcing alternatives to ensure treatment for patients. However, despite the early advocacy efforts by the EAHP reports on medicines shortages continued to materialise at increasing speed throughout Europe. In particular the percentage of hospital pharmacists reporting shortages to be an issue in terms of delivering the best care to patients has seen a significant increase with 91.8% of the 2018 Medicines Shortages Survey respondents, compared to 86.2% in 2014, stressing that medicines shortages are a problem faced in their hospital pharmacy. Similarly also the types of medicines most commonly in shortage have seen an increase in particular antimicrobial agents (57% in 2014 | 77% in 2018), preventative medicines (20% in 2014 | 43% in 2018) and anaesthetic agents (27% in 2014 | 39% in 2018). During the launch event of its 2018 Medicines Shortage Survey Report in November 2018, the EAHP called on the European Commission and the European Medicines
António Gouveia , EAHP Scientific Committee Member
Daily dose
EAHP POLICY ARTICLE
or a number of years, the EAHP has been advocating on the issue of medicines shortages and its threat to patient care in hospitals. In 2012, the Association published its position paper on medicines shortages which stressed that communication between the different actors involved in the supply of medicines is key. The paper contained recommendations for hospital pharmacists, prescribers, wholesalers, manufacturers as well as regulatory bodies that could help to tackle the panEuropean problem of medicines shortages.
And this is not all, we also have to consider the risk of shortages. In drug purchasing this is a well known problem, one which is not yet evident in biosimilars. But these are complex drugs, expensive to develop and manufacture, using sensitive processes. Not many companies are competing in this market. If purchasing practices by big consumers such as national health services put too much stress on this market (for instance by concentrating purchases on very few suppliers), then the risk of shortages will increase and we will have a new problem. So, really, there are lots questions that you probably have already asked yourself. If this is the case, it is a good idea to come to this seminar and listen to our speakers and discuss together possible solutions to face the challenge of procurement of biosimilars.
Agency (EMA). On the one hand the Association would like to see a European level investigation into to causes of medicines shortages led by the European Commission. On the other hand a reliable catalogue of medicines in shortage across Europe is needed listing the shortage reason, estimated duration and other advice to pharmacists, prescribers and patients. Such a comprehensive communication should be led by the EMA which currently is looking together with the Heads of Medicines Agencies (HMA) via a joint task force at the availability of authorised medicines. It is time to act now since interest of European institutions is growing. The Council Recommendation on strengthened cooperation against vaccine-preventable diseases, which was released in December 2018, recognised for instance the issue of vaccine shortages. Also, the head of the EMA – Guido Rasi – acknowledge the problem of Brexit at Politico’s Health Care Summit in fall 2018 where he stated that the agency expects some shortages to happen due to Brexit. To ensure that the problem remains high on the EU’s agenda, also after the European Parliament elections in May 2019, the EAHP will continue to distribute the findings of its 2018 Medicines Shortages Survey report and engage with relevant actors at European level. In case you are interested to find out more about the pan-European problem of medicines shortages join the Synergy Satellite “Facing Brexit and FMD - Is Europe ready for the double “storm”?” on Thursday, 28 March 2019 from 7:00am to 8:30am at room 211. The Synergy Satellite will address the medicines shortages problem in light of the new challenges that lie ahead of hospital pharmacists such as the implementation of the Falsified Medicines Directive (FMD) and Brexit. Stephanie Kohl , EAHP Policy & Advocacy Officer
Daily dose Check the electronic version!
All congress participants have now the opportunity to see in advance what is in the congress newspaper the Daily Dose. Stay tuned to your mailbox!
n the i e g a Eng te at a b e d r Twitte
P19
#EAH
24th Congress of the EAHP
6
SYNERGY EVENT: PREVIEW & SPEAKERS
ANTICOAGULATION
IMPROVING EFFICACY AND PREVENTING SIDE EFFECTS – SPONSORED BY AN EDUCATIONAL GRANT FROM BAYER –
Wednesday, 27 March 2019 / 14.45 to 16.15 / room 116 Thursday, 28 March 2019 / 08.45 to 10.15 / room 116
24TH Congress of the EAHP, 27-29 March 2019, Barcelona, Spain
Anticoagulation – Improving efficacy and preventing side effects ANTICOAGULANT ARE COMMON AND IMPORTANT Approximately 1% of the population is prescribed longterm oral anticoagulation. A majority of anticoagulated patients receive an anticoagulant for one of the following conditions or indications: mechanical prosthetic valves, atrial fibrillation (AF) and (recent) venous thrombo-embolic disease. If these patients are treated insufficiently, they have an increased likelihood of experiencing thrombosis and death. For example, an un(der)treated patient who has been diagnosed with an obstructive prosthetic valve thrombosis has an associated mortality of approximately 10%. MORE PATIENTS ARE USING ORAL ANTICOAGULANTS Oral anticoagulants have recently seen a large increase in uptake due to the development and subsequent marketing of non-vitamin K oral anticoagulants (NOACs). In contrast to the older vitamin K antagonists (VKA), these newer compounds can be used in fixed doses (i.e. without a need for systematic therapeutic drug monitoring), taking into account patient parameters as weight or renal function. NOACs have shown to be at least as effective as VKA, the former standard of therapy, in multiple settings. Ruff et al showed in their Lancet meta-analysis that NOACs were associated with fewer major bleeds, fewer intracranial hemorrhages and had a lower all-cause mortality compared to warfarin in atrial fibrillation. PAT I E N T S R E G U L A R LY H AV E T O I N T E R R U P T THERAPIES Each year approximately 1 in 10 patients will undergo an
interruption to their anticoagulant therapy due to a surgical procedure. Correct use of anticoagulant drugs should be ensured at all times during hospital stay, given the high risk of iatrogenic and hence mostly avoidable harm. In particular, overtreatment and undertreatment can lead to bleeding and thrombotic events respectively, bearing in mind that any bleeding event will inevitably lead to discontinuation of all antithrombotic therapies. Therefore, hospital pharmacists should become involved in mitigating the peri-procedural bleeding risk due to inappropriate therapies. Lorenz Van der Linden will provide information on these basic necessities regarding safe inpatient use of oral anticoagulation. Lorenz attained his PhD in 2018 with his dissertation on improving drug use in older inpatients. Given the high prevalence of cardiovascular morbidities in older adults, his investigations and clinical experiences have fueled his longstanding but still ongoing interest in cardiovascular therapies. MAN VERSUS MACHINE …. MAN AND MACHINE? Nevertheless anticoagulants are considered as high risk medication, there are simply too many inpatients per day for many, if not most, European hospital pharmacies to evaluate all therapies by a trained hospital pharmacist. But it is possible to use a computer to identify the patients at risk and advanced clinical decision support systems (aCDSS) might be the final piece in solving this problem. Charlotte Quintens is currently doing PhD research on the development, validation and implementation of advanced clinical rules and prediction algorithms, and evaluating their impact on drug-related problems, such as incorrect
dosing of NOACs, undertreatment in AF or postoperative overtreatment with low molecular weight heparins. WHAT TO EXPECT? Two speakers, grounded in clinical practice, will show in an interactive session how to get involved in thrombocardiology and periprocedural (non)bridging therapies. Learning objectives of the Synergy seminar comprise the very basics of periprocedural management of anticoagulants and the opportunities to provide targeted support by using clinical rules integrated in the hospital information system. This includes identifying the bleeding risk of the (planned) procedure as well as the thrombotic risk of the individual patient undergoing the procedure. The real aim is to promote the development of a hospital’s ‘anticoagulation stewardship program’ in which the hospital pharmacist must participate actively. Thomas De Rijdt, EAHP Scientific Committee Member
Follow us on
eahpofficial
BARCELONA INFORMATION
Things to do in Barcelona
B
esides being unique because of its own way of life, Barcelona is also remarkable for its rich historical and cultural heritage. The Barri Gòtic (Gothic Quarter) is the centre of the old city of Barcelona where you can admire roman and medieval buildings and wander in its narrow and winding streets. As a prominent artistic centre, Barcelona is also loved due to the Catalan modernista architecture which developed between 1885 and 1950, and that is associated to the movement known in Europe as Art Nouveau. One of the most important representatives of this movement is the Spanish architect Antoni Gaudi, whose spectacular works can be seen throughout the city. His best-known work is the unfinished but breathtaking church of e Sagrada Família, also generally recognized as the symbol of Barcelona. Particularly renowned is also the ambitious work of art La Pedrera, a fascinating and unusual building that hosts today a cultural centre dedicated to a wide range of cultural activities and expositions. Barcelona is also highly appreciated for its botanical and thematic parks. The Park Güell, designed by Antoni Gaudi, is a magical garden located on the hill of El Carmel in the Gràcia district where you will gaze in wonder at the gatehouses, based on designs recalling the fairy tale of Hansel and Gretel, and at the famous and colorful mosaic lizard. Also to discover, there is the largest park of Barcelona, so called Montjuïc, and located on the mountain of the same name. It is home to the buildings from the 1992 Olympic Games, the famous Castell de Montjuïic, the great museum Fundació Joan Miró with a collection of paintings, sculptures and graphic pieces by the Spanish surrealist artist. A must-see are also the spectacular show of the Magic Fountain and the Poble Espanyol, with its “artisans’ village”. So do not miss the opportunity to climb to the
EUROPEAN JOURNAL OF
HOSPITAL PHARMACY
heights of these parks and enjoy the beautiful panorama and its treasures. Considered as one of the liveliest European destinations, the city of Barcelona will also surprise you by its numerous venues for live music and theatre, including outstanding concert halls. You will marvel at the Palau de la Música Catalana for its Modernista architecture and at the performances of the Gran Teatre del Liceu opera house. We then warmly invite you to sample the heart of the Barcelona “movida” at some point during the 24th Congress of the EAHP by making a detour via La Rambla, a gorgeous tree-lined pedestrian walkway full of artists, human statues, fortune-tellers, musicians and dancers. To get further information on the large variety of cultural events, shopping, top gastronomic venues and sightseeing opportunities offered by the City of Barcelona, please visit the Barcelona Tourist Office’s official website www.barcelonaturisme.com.
Speak to us at stand #9 for more on the new biologicals and biosimilars learning modules!
24th Congress of the EAHP
7
STATEMENT IMPLEMENTATION
The future of the profession: 5 years since the adoption of the European Statements
T
his year will mark the fifth anniversary since EAHP adopted the European Statements of Hospital Pharmacy. The 44 European Statements represent what every European health system should aim for in the delivery of hospital pharmacy services, maximizing benefits and minimising risks for patients.
A lot has been progressed since an Implementation team (led by EAHP Project Director Tony West) was set up in April 2016 as a way to help our members to bring about the full achievement of the European Statements within their countries. The first actions carried out by the team was the design of a strategic implementation plan and the set-up of support networks. A network of Implementation ambassadors was set up with the help of our national associations. Implementation Ambassadors provide a key support to the project at the national level and act as primary link between EAHP, national associations and the implementation activities carried out within their countries. A total of 3 meetings and 2 trainings of ambassadors have been organised since the project started. These meetings are a perfect opportunity to brainstorm the latest initiatives and to update each other not only on the progress made, but
also on the challenges faced during the project.Since the project started, awareness has increased by 20 %. This has been achieved thanks to an awareness campaign developed by the implementation team with the help of our members, ambassadors and a strong network of volunteer translators. The awareness campaign includes (among other things): a dedicated website for the project and the European Statements, brochures and flyers that have been translated into national languages and a video to promote the Statements and our latest initiatives was shot by EAHP. EAHP also developed and launched last year during the 23rd EAHP Congress in Gothenburg two initiatives: the EAHP online self-assessment tool and the Statement Implementation Learning Collaborative Centre (SILCC) programme.
The online self-assessment tool allows hospital pharmacists to assess the level of Statement implementation within their hospitals while providing a tailor-made action plan and resources to help your pharmacy move towards implementation. At the
Keynote 2: Clinical human factors – delivering healthcare under pressure
H
Doctor Jane Carthey
Human Factors expert and patient safety specialist
As a way to help individual hospitals to better understand pharmacy procedures linked to the Statements, EAHP launched last year the SILCC programme. This programme allows hospital pharmacists (SILCC Fellows) to visit hospitals (SILCC Hosts) from other members countries to learn about pharmacy procedures linked to the Statements. 9 hospitals have been approved as SILCC Hosts and the first SILCC Fellows will join the programme in April 2019. Come to the booth to learn how you can join the programme. A lot has progressed since the adoption of the Statements in 2014. Don’t hesitate to come to the booth 32 to learn more about what EAHP is doing to implement the European Statements within our members countries.
KEYNOTE 2: PREVIEW & SPEAKER BIO
ealthcare is about providing the best therapy to patients with a focus on quality and patient safety. As every patient and situation is unique, the work environment is dynamic and the circumstances are often unpredictable. This places healthcare providers, teams and organisations under high pressure. In such intense situations, decision making can be compromised, impacting on the quality of care, clinical outcomes and potentially causing harm to the patient. In short, human factors not technical inability can lead to this unwanted situations. This interaction between people and their environment is studied in ‘human factors’ (also known as ergonomics).
moment when this article was written, 110 hospital assessed their pharmacies using the tool. Stop by the EAHP Booth 32 at the exhibition area and ask the implementation team to give you a quick demonstration.
Human factors is a discipline that considers both the physical and mental characteristics of people as well as the organisational factors or wider sociotechnical system. It is the application of scientific methods to the design and evaluation of tasks, jobs, equipment, environments and systems to make them more compatible with the needs, capabilities and limitations of people. The principles and practices of human factors focus on optimising human performance through better understanding the behaviour of individuals, their interactions with each other and with their environment. In healthcare human factors can advance human performance, optimise wellbeing, improve both staff and patient safety as well as experience and enhance the overall system performance. Doctor Jane Carthey is a Human Factors expert and patient safety specialist who worked on safety culture. In her PhD research she explored teamwork, communication and decision making during simulated emergency exercises. She works with NHS boards to improve their safety culture and holds an active research portfolio on human factors and surgical outcome, identification of system failures that lead to adverse drug events, incident reporting, organisational safety culture, procedural non-compliance and improving handovers.
The Clinical Human Factors Group is a charity that works with healthcare professionals, managers and serviceusers partnering with experts in human factors from healthcare and other industries to campaign for change in the NHS and healthcare. Their vision aims at developing a healthcare system that places an understanding of human factors at the heart of improving clinical, managerial and organisational practice leading to significant improvements in safety and efficiency.
EAHP Implementation Team
EAHP photo corner
Visit the photo corner!
If you want answers to questions like “What are clinical human factors?”, “What is their relevance to me and my practice?” and “Isn’t this all too touchyfeely?” you have to join today’s keynote session. Your team and organisation as well as your patients might benefit from it! Thomas de Rijdt, EAHP Scientific Committee Member
K E Y N OTE
2
Forum Auditoriu m Thursday 28 11.15 - 12.1 5
The EAHP photo corner is located next to the Cyber Café
24th Congress of the EAHP
8
SURVEY RESULTS
2018 EAHP Statements Survey The 2018 EAHP Statements Survey completed the second cycle of new EAHP Surveys.
It was conducted from October 2018 to November 2018 with the focus on the Statements from the following sections: Section 1: Introductory Statements and Governance Section 3: Production and Compounding Section 4: Clinical Pharmacy Services 35 countries participated in the survey. 5164 hospital pharmacies were asked to participate and 719 of those completely answered the questionnaire. The overall response rate of the survey was 14%. There are 9 countries with a response rate of over 50% and another 11 with 50 to 25%. While the overall response rate is comparable to the last survey and reasonable for this type of survey, it remains challenging in France, Turkey and Italy, which is nearly 50% of the addressed hospital pharmacies. The country with the highest absolute number of 99 complete responses was Germany. Which three Statements are the highest priority for you to implement first?
1.1 The overarching goal of the hospital pharmacy service is to optimise patient outcomes through working collaboratively within multidisciplinary teams in order to achieve the responsible use of medicines across all settings. 4.1 Hospital pharmacists should be involved in all patient care settings to prospectively influence collaborative, multidisciplinary therapeutic decision-making; they should play a full part in decision making including advising, implementing and monitoring medication changes in full partnership with patients, carers and other health care professionals. 4.8 Clinical pharmacy services should continuously evolve to optimise patients’ outcomes. While the three below were deemed to be the most challenging to implement::
1.1 The overarching goal of the hospital pharmacy service is to optimise patient outcomes through working collaboratively within multidisciplinary teams in order to achieve the responsible use of medicines across all settings. 4.1 Hospital pharmacists should be involved in all patient care settings to prospectively influence collaborative, multidisciplinary therapeutic decision-making; they should play a full part in decision making including advising, implementing and monitoring medication changes in full partnership with patients, carers and other health care professionals.
Cyber Café Fill in the Evaluation Forms of the sessions you attended in order to receive your ACPE accreditation certificate and Certificate of attendance. Also register during the Congress for the Synergy Masterclass 2019 to get 10% discount at the Cyber Café
Looking deeper into the results of the answers provided to the Statements at the country level, there were no big changes compared to last year’s results. More interestingly, the barriers for pharmacists to implement the Statements are very often “other healthcare professionals are doing this”, “lack of capacity” and “the manager does not consider this as a priority for the hospital pharmacy”. From this we can conclude whom we need to address and collaborate more intensively in the hospitals to further promote and find supporters for the implementation of the Statements. More the capacity than capability, in many cases, seems to remain a main barrier. Unfortunately, our capacities are more often spent for instance on drug shortages rather than the implementation process. Regarding the awareness, agreement and commitment with the Statements, the results show a constant satisfactory level. This is a positive result considering that Statement awareness has increased over the last 4 years. The success in this regard is attributed to the activities of the Statement implementation team and all of the ambassadors in EAHP’s member countries. The complete survey report will be available to EAHP member associations shortly. A comprehensive analysis of the results will be submitted as a publication to the European Journal of Hospital Pharmacy (EJHP). EAHP wishes to thank all hospital pharmacists and all national coordinators, who contributed to the success of this survey. The data from EAHP Surveys are very important as it provides critical information to further the Statements Implementation project. EAHP strongly believes that higher levels of implementation will result in better outcomes for European patients. Steffen Amann, Aida Batista and Petr Horák, EAHP Board leads for EAHP Survey
presentations
A
re you too busy to review all of the posters? EAHP has made a selection and is dedicating two sessions to oral presentations by the authors of the top nominated posters. At 10.30 on Wednesday, in room 116 and 115, 16 authors will explain their work in short presentations, which will each be followed by a Q&A session. The Award Nominee oral presentations group includes: (Room 116)
•
•
• •
FREE WI–FI SERVICE WILL BE
•
AVAILABLE THROUGHOUT THE CONGRESS CENTRE AND IN THE CYBER CAFÉ SPONSORED BY
•
• •
•
Password: ROCHE2019
Overall, the large majority of participants did not identify Section 3 as a high priority in terms of implementation and consequently ranked it as the least challenging Section to implement. These outcomes can probably be attributed to the fact that the Statements on “Production and Compounding” are already well established in hospital pharmacies.
Award nominee and GPIs oral
•
WiFi network name: EAHP_ROCHE
4.2 All prescriptions should be reviewed and validated as soon as possible by a hospital pharmacist. Whenever the clinical situation allows, this review should take place prior to the supply and administration of medicines.
•
Network Meta-Analysis Of First-Line Antiangiogenic Drugs In Advanced Renal Cell Carcinoma Hot-Melt Ram Extrusion 3d Printing: A Smart Method For Compounding Orodispersible Films In Hospital Pharmacies Encouraging The Responsible Use Of Antibiotics: Awareness And Understanding Among A University Student Population Of A Community Pharmacy Public Health Campaign In Scotland Chemotherapy Near The End Of Life In OncoHaematological Adult Patients Impact Of Pharmaceutical Interview In Patient Acceptance Of Insulin Glargine’s Biosimilar 100ui/Ml Determining The Necessary Components Of A Pharmaceutical Care Complexity Screening Tool: An E-Delphi Study A Systematic Review Of Pharmacist Input In The Screening, Management And Prevention Of Metabolic Syndrome Drug-Drug Interactions In Patients With Cardiovascular Diseases Switching From Individualised Nutrition To Standardised Or Commercialised Nutrition In Newborns: Are There Any Possibilities? Toxicity With 5-Fluorouracil And Irinotecan: Interest Of Genotyping In Patient Care A Pilot Randomised Double-Blinded PlaceboControlled Trial Of Prophylactic Sildenafil In Preterm Infants At Risk Of Bronchopulmonary Dysplasia
The Good Practice Initiative oral presentations group includes: (Room115) • •
•
• • •
•
Excessive Reorders: A Contest Reduces Workload Development Of New Production When Neither Packaging Nor Some Of The Raw Materials Conform To European Standards How To Handle Active And Placebo Drugs For A Clinical Trial In The Production System Cato In Order To Secure The Blind And To Ensure The Exact Same Preparation Of Active And Placebo Products Improving The Continuit y Of Care In Case Of Extratemporaneous Medicines For Children Using An Electronic Algorithm To Identify The Most Relevant Patients For Medication Review Let’s diversify to guarantee access to the hospital pharmacist’s expertise: All good things come in fours!
Involving patients in a workshop focused on communication skills: a proof of concept of experiential training for residents in hospital pharmacy
Come along to applaud and benefit from your colleagues’ hard work and creativity!
24th Congress of the EAHP
9
SYNERGY EVENT: PREVIEW & SPEAKERS
BIOSIMILARS
SYNERGY SATELLITE EVENT
challenging misconceptions, optimising uptake, maximising value
The eAhP inviTes you To ATTend The 2019 synergy sATelliTe session:
WEDNESDAY, 27 MARCH 2019 17:00 TO 18:30 > ROOM 116 THURSDAY, 28 MARCH 2019 13:30 TO 15:00 > ROOM 116
24th Congress of the EAHP 27-29 March 2019, Barcelona, Spain
FINANCIAL SUPPORT WAS PROVIDED BY PFIZER LIMITED AS A MEDICAL AND EDUCATIONAL GOODS AND SERVICES
Biosimilars challenging misconceptions, optimising uptake, maximising value Biosimilars – so what is new? Over the past decade, the use of biological medicines has become commonplace in hospitals across Europe. They have helped to transform the lives of many people with serious illnesses, but their use has been limited by their relatively high acquisition cost and, in some conditions, their marginal cost-effectiveness. Many biosimilars have come to market in recent years at a lower price and use is now widespread in many countries. However, as we will see at this Synergy session, the is significant variation in the use of biosimilars across Europe and even within different areas of the same country. Why do we have this variation in use of biosimilars? There still seems to be reluctance in some places to use biosimilars. The reasons for this will be explored at this session and participants are invited to bring along their own stories about how this is in their hospital. It may be that some people see biosimilars as ‘cheap and inferior’ and are not aware of the stringent regulatory requirements of the EMA. Or other factors may be at play.
So what can I do about it? The implementation of evidence in clinical practice is complex and requires careful thought and persistence to encourage this to happen. This Synergy Satellite features two speakers who have achieved great successes in the use of biosimilars and will present examples of how this was achieved. This required a multifaceted approach to implementation involving education, problem-solving, financial incentives as well as audit and feedback. We will also look ahead to the biosimilars coming to the market in the next few years and discuss the specific challenges these may offer. Who are the speakers at this session? Dr Mathias Flume is Head of Business Unit Prescription Management at KVWL Dortmund in Germany. He will tell us about his experience in supporting the use of biosimilars in Germany, the challenges they faced and how they overcome them. Anita McWhirter is the New Models of Care Pharmacist for the Royal Marsden in London UK, a specialist oncology hospital. She will tell us about the work she led on the implementation of Biosimilar Trastuzumab as well as the Cancer Vanguard
Crossword Puzzle 1
2
5
6 7
8
9
11
12
13
10
14 15
16 17
18 19
20
22
24
s
p you check that you have prepared intravenous drugs ct? ere does the drug information tool have an inquiry form? k it out at booth 39! me to BD booth #5 to talk about _ _ _ _ _ e Country where Haemopharm Healthcare is based scribe H+H SYSTEM storage product advantages in one
hat can Rees Scientific help you with? hat product is being displayed in booth 11?
21
Use of biosimilars is one of the biggest challenges facing hospital pharmacists to ensure value for money is attained within healthcare. Their use will release funds that can be invested elsewhere within the healthcare setting as well as widen the access to the use of biologics to those where their use was were previously deemed not to be cost-effective. If your hospital is struggling to encourage the uptake of biosimilars then come along and hear about these excellent examples and go away inspired to make a difference! Jonathan Underhill, EAHP Scientific Committee Member
Complete one of the crossword puzzles included in the Wednesday and Thursday Daily Dose, bring it to the EAHP booth #32 and enter a prize draw to win a free registration for the 25th EAHP Congress in Gothenburg (25 – 27 March 2020). ACROSS
3
4
work on rituximab. Jonathan Underhill is Medicines Clinical Adviser at NICE in the UK and will facilitate this session Why should I come along to this? This session is relevant for all pharmacists involved in hospital pharmacy, particularly those working in therapeutic areas where biologics are used such as oncology, rheumatology, gastroenterology and dermatology.
2. Help you check that you have prepared intravenous drugs correct? 3. Where does the drug information tool have an inquiry form? Check it out at booth 39! 4. Come to BD booth #5 to talk about _ _ _ _ _ _ 7. The Country where Haemopharm Healthcare is based 8. Describe H+H SYSTEM storage product advantages in one word. 12. What can Rees Scientific help you with? 15. What product is being displayed in booth 11? 16. The brand name of the Compounder Family. You can find the answer in booth number 50. 18. New brand of Automated Dispensing Cabinets from TouchPoint Medical. Find answer at booth 68 21. How many hospitals have joined the SILCC programme / or have become SILCC Hosts? 22. Where did the 1st EAHP Training of Implementation Ambassadors take place? 23. One less thing to worry about – Learn more at stand nº30 24. Which is the last organization to endorse the 44 European Statements of Hospital Pharmacy?
DOWN
1. Please join one of our Sandoz booth activities (#27) to receive the answer. 2. ICU Medical’s Automated Compounder with Remote Verification (Booth 48) 23 5. What type of medicine do European hospital experience shortage most commonly? 6. What does the W in UW stand for? Ask Bridge to Life if you don’t know the answer. 9. Come by booth #59 to find the answer! 10. What association brings together pharmacy students from all over Europe? 11. How many hospitals have joined the SILCC programme / or have become SILCC Hosts? 13. Unit Dose Done Right. Easiest way to package meds . 14. What is the smart solution for optimal medication management called? Created using the Crossword Maker on TheTeachersCorner.net 17. In which country are the headquarters of Fresenius Kabi based? Down 19. ACCP’s premier specialty recertification program for BCPSs 1. Please join one of our Sandoz booth activities (#27) to receive 20. Which system simplifies the identification and registration of medication? the answer. 2. ICU Medical’s Automated Compounder with Remote Verification (Booth 48) FULL NAME: 5. What type of medicine do European hospital experience shortage most commonly? EMAIL: 6. What does the W in UW stand for? Ask Bridge to Life if you don't know the answer. 9. Come by booth #59 to find the answer! 10. What association brings together pharmacy students from all
24th Congress of the EAHP
10
Take part in the Bayer “Meet the expert” sessions Booth no 19
Wednesday 27th March
Thursday 28th March
10.45 - 11.15
12.20 - 12.50
13.45 - 14.15
12.50 - 13.20
Rivaroxaban: Tailored Protection for Your CardioVascular Patients Expanding Clinical Evidence to CAD and PAD Speaker - Leandro Agati Rivaroxaban: Tailored Protection for Your CardioVascular Patients Translating Clinical Evidence Into Practice Speaker - Lorenz Van der Linden
Rivaroxaban: Tailored Protection for Your CardioVascular Patients Expanding Clinical Evidence to CAD and PAD Speaker - Leandro Agati Rivaroxaban: Tailored Protection for Your CardioVascular Patients Translating Clinical Evidence Into Practice Speaker - Lorenz Van der Linden
Student Programme
STUDENTS
EAHP – EPSA Internship Platforms
I
n the first edition of Daily Dose at the 24th Congress of the EAHP we will explore how EAHP is helping pharmacy students with developing their professional competences and make them become better healthcare professionals. Presenting us with a first-hand experience with EAHP – EPSA Internship Platform are Calum Johnson from the UK and Nikolaus Linder from Austria, having had their internships in Germany and Spain in 2018. First, thank you for joining us here and sharing your insights on the internship you did in the hospital pharmacy.
How would you describe the whole experience in one sentence? Calum (C): A great opportunity to widen my understanding on the role of the pharmacist outside of the UK. Nikolaus (N): I will never forget it and would instantly do it again!
Do you feel the Internship Platform has helped you to develop your skills and advance your knowledge of Hospital Pharmacy? N: Through this internship I gained a lot of new knowledge, particularly in the fields of clinical pharmacy and psychopharmacology. This also changed my approach to work back home. However, the experiences made abroad not only helped me to grow professionally, but more importantly made me grow as a person. C: Undoubtably. I have found that having this experience has not only developed my understanding of drugs that I would not normally work with in the UK but has also helped me developed transferrable skills such as independent learning. Most of all, it has helped me value working outside of my comfort zone which will help me in my future career.
What were your main tasks during the internship and how did you collaborate with the hospital staff? C: At Universitӓtsklinkum Leipzig, my main task was to investigate how the recommendations of pharmacists at the hospital were received by the doctors and whether they were implemented into patient care plans. This was great preparation for my research project that I am currently
working on for my fourth year at university as it helped me learn to manage my time well and set personal goals. Aside from the research project, I also was able to sit in on patient consultations with the pharmacy staff which helped me improve my communication skills and provided me with different techniques for communicating with patients that I would not have considered. At the end of my placement, I prepared a presentation detailing the work I had done while I was there and a demonstration on how to use the database I had produced so the data could be continued to be added to what I had already collected. N: During my internship I was allowed to shadow the chief pharmacist of a psychiatric hospital in Spain. The main tasks included validating doctor’s prescriptions, medication management and compounding. Moreover, I was able to help with research projects and got to see other hospital pharmacies – even a pharmacy in a prison, which was quite an exceptional experience for an Austrian student! Wherever I went, I always received a warm welcome and everyone, whether doctors, nurses, pharmacists or technicians, tried to give me a good overview of their workplace and the Basque healthcare system.
Would you recommend the hospitals to enter the EAHP – EPSA Internship Platform pool of available placements for students and young professionals? N: I would definitely recommend any hospital to enter the EAHP – EPSA Internship Platform. Not only the exchange student, but also the pharmacy team will profit of such an experience. Through this programme you meet new people, get to know different cultures and can compare different healthcare systems – definitely a win-win situation! C: Yes, I would. For me, it was the additional benefit of being able to improve my German speaking skills that made me want to apply and I feel if there were more hospitals available from different parts of the world, the opportunity to undertake this kind of placement would be more accessible to different people. Thank you very much for taking your time, if you have any encouraging words to students thinking about applying for the internship you can make their decision easier now.
SYNERGY SATELLITE EVENT The eAhP inviTes you To ATTend The 2019 synergy sATelliTe session:
WEDNESDAY 27 MARCH 14.45 - 16.45 How can hospital pharmacists implement antimicrobial stewardship to ensure rational use of antimicrobials? Hospital pharmacists should be involved in multi-disciplinary antimicrobial stewardship teams by ensuring patients receive the appropriate antimicrobial at the correct dose and duration, minimising the abuse and misuse of antibiotics and minimising the development of antimicrobial resistance.
C: I have been repeatedly complimented on my CV thanks to the addition of an international placement when I have been applying for pre-registration placements. The length of the placements also shows how dedication for learning more, moving out of your comfort zone and improving foreign language skills. Aside from improving career prospects, it has also been an unforgettable experience for the people I have met and places I have been able to see. I can’t thank the EAHP enough for the opportunity and how easy they made it to apply and get into contact with the hospitals to organise the placement. N: If you are thinking about applying, don’t overthink it too much, just do it! It will be an unforgettable experience, I am sure. Nejc Klopčič, EPSA Vice President of External Relations
24th Congress of the EAHP
11
SYNERGY EVENT: PREVIEW & SPEAKERS SYNERGY SATELLITE EVENT The eAhP inviTes you To ATTend The 2019 synergy sATelliTe session:
Brexit, FMD and shortages – are hospital pharmacists prepared for the stormy times ahead? 2019 will be a turbulent year holding m a ny c h a l l e n g e s f o r h o s p i t a l pharmacists who already now regularly find themselves having to manage the impact of medicines shortages as revealed by EAHP’s 2018 Medicines Shortages Survey. To ensure that hospital pharmacists are informed about the Falsified Medicines Directive (FMD), medicines shortages and the issues that could potentially be caused by Brexit, the Synergy Satellite ‘Facing Brexit and FMD - Is Europe ready for the double “storm”?’ was included on this year’s congress programme.
change for the hospital pharmacy profession. As one of the key persons on the side of the European Commission, Ms Mathieu-Mendes is the most suitable individual to talk about FMD and the verification and decommissioning obligation of hospital pharmacists linked to this piece of legislation. In addition she will reflect on the issue of medicines shortages from the perspective of DG SANTE.
Given the challenges that lie ahead of the hospital pharmacy profession, the speakers of this Synergy Satellite were asked to reflect on how much are other EU countries affected by Brexit. In addition, they should outline if medicines policy in the EU will be influenced by medicines shortages, the relocation of the European Medicines Agency (EMA), FMD and Brexit.
Dr Monica Dias – as Policy and Crisis Coordinating Officer working in the office of the Deputy Executive Director at the EMA – is perfectly equipped to provide the audience with information about Brexit and the relocation of EMA. Her involvement in the Heads of Medicines Agency (HMA)/EMA Task Force on the availability of authorised medicines allows her also to share insights from this initiative and to comment on the growing problem of medicines shortages in European hospitals.
Agnès Mathieu-Mendes, Deputy Head of the Unit dealing with the quality, safety and innovation of medicinal products in the Directorate General on Health and Food Safety (DG SANTE) in the European Commission, will share her insights on the latest and most impactful regulatory
As Policy & Advocacy Officer of the EAHP, Stephanie Kohl will describes the feeling of the hospital pharmacy profession about FMD by outlining the main challenges that were faced during the implementation phase and the practical issues and barriers that
were encountered after 9th February. In relation to medicines shortages, Ms Kohl will present feedback from EAHP shortages survey which shows that better communication, proposals and good practices should be shared as a solution to prevent and solve shortage problems.
24th EAHP Congress 27 th - 29 th March 2019 | Barcelona, Spain Personalised hospital pharmacy Meeting the needs of every patient
If you want to gain a better understanding about whether the relocation of EMA and Brexit may influence medicine policy in the EU and how FMD affects medicines accessibility and the workload of hospital pharmacies, join the discussion on Thursday, 28 March 2019 from 7:00am to 8:30am at room 211.
Despina Makridaki– EAHP Scientific Committee Member
EAHP 2019 is available in app stores for IOS, Android devices and on the Web. Search for “EAHP2019” The EAHP2019 App is brough to you by
Download the QR code reader to yout phone, open it & you are ready to go!
Unit Dose Done Right
Unit Do se Bar Cod , ing, Pharma c Nursing y & Supply Experts !
• Ultraviolet Inhibitant • Moisture Resistant • Tamper-Evident • Cold Seal • 6 and 12-month Beyond-Use Dating • 1-D and 2-D Bar Coding • Flexible Label and Report Formatting • Multiple Sizes to Fit Your Meds and Storage Needs
Simple. Reliable. Distributed in Europe by Pero’s PEROS LOGO
27/04/10
14:17
Page 1
Please see us at Booth #22
Lyon-France +33.478.627.713 www.peros.fr contact@peros.fr